Technical analysts note dna stock price staying above its trendline support, with RSI readings near 58 suggesting potential room for further upside. This product should be just the beginning of CRISPR Therapeutics' growth story because the company applies this technology throughout its pipeline -- a pipeline that includes gene-editing candidates in the areas of immuno-oncology, autoimmune diseases, and cardiovascular disease. The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock. The latest dna stock price hovered around $1.09 in early June trading, reflecting a slight uptick of 1.87% intraday. Analysts point to growing investor interest in biotechnology plays despite broader market volatility.